Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT101 Norovirus Vaccine in Healthy Adults
NCT07818629Phase 1Recruiting
- Sponsor
- InThera
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of INT101 in norovirus infection and norovirus gastroenteritis (4 arms), sponsored by InThera. Primary endpoints: Incidence of Immediate Adverse Events, Incidence of Solicited Local Adverse Events and 4 more. Started Aug 2026; status: recruiting.
02
Drugs
INT101
03
Conditions
norovirus infectionnorovirus gastroenteritis
Beyond the preview
Go deeper on NCT07818629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818629.